Heinsen, Laurits Juhl
Pararajasingam, Gokulan
Andersen, Thomas Rueskov
Auscher, Søren
Sheta, Hussam Mahmoud
Precht, Helle
Engdam, Kalle Brunebjerg
Hangaard, Jørgen
Lambrechtsen, Jess
Knop, Filip Krag
Egstrup, Kenneth
Funding for this research was provided by:
Region of Southern Denmark
Syddansk Universitet
Article History
Received: 12 December 2022
Accepted: 5 April 2023
First Online: 28 April 2023
Declarations
:
: F.K.K. has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, ShouTi, Zealand Pharma and Zucara; and is a minority shareholder in Antag Therapeutics Aps. The remaining authors declare that they have no conflict of interest to disclose.
: All methods in the present study carried out in accordance with relevant guidelines, and the study was approved by the Regional Committees on Health Researh Ethics for Southern Denmark (ID S-20150029) as well as the Danish Data Protection agency (ID 2008-58-0035). The study was registered at clinicaltrials.gov (protocol ID: NCT03016910). All participants provided written informed consent to participate in the study prior to inclusion.
: Not applicable.